Related Experiment Videos
Abstract:
The effect of ceftizoxime, a new aminothiazolil-syn-methoxy-iminocephalosporin has been evaluated on 169 strains of Gram negative bacilli isolated from hospitalized patients and compared with that of cefotaxime and of ceftriaxone. The effect of these 3 cephalosporins and of cefalotin was also evaluated on 50 strains of staphylococcus. CIM50 of ceftizoximel was as follows: K. pneumoniae less than .032, aureus and S. epidermidis less than .2 CIM90 for the same species was: K. pneumoniae less than .25, E. coli less than .63, E. Cloacae and S. marcescens less than 8, S. aureus less than 32, S. epidermidis less than 16. The values obtained with cefotaxime and ceftriaxone were similar. Cefalotin was clearly more active on staphylococcus strains with CIM50 and CIM90 for both species of less than .25 and less than .2 respectively.
Insights
Ceftizoxime, a novel cephalosporin, demonstrates potent activity against Gram-negative bacilli, comparable to cefotaxime and ceftriaxone. It also shows efficacy against Staphylococcus strains, though cefalotin exhibits greater activity in this regard.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Gram-negative bacilli and Staphylococcus species are common causes of hospital-acquired infections.
- Aminothiazolyl-syn-methoxy-iminocephalosporins represent a class of antibiotics with broad-spectrum activity.
- Evaluating new antibiotics like ceftizoxime is crucial for combating antimicrobial resistance.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of ceftizoxime against Gram-negative bacilli and Staphylococcus strains.
- To compare the efficacy of ceftizoxime with cefotaxime, ceftriaxone, and cefalotin.
Main Methods:
- Antimicrobial susceptibility testing was performed on 169 Gram-negative bacilli and 50 Staphylococcus strains.
- Minimum Inhibitory Concentrations (MIC50 and MIC90) were determined for ceftizoxime, cefotaxime, ceftriaxone, and cefalotin.
Main Results:
- Ceftizoxime exhibited potent activity against Gram-negative bacilli, with MIC50 values below 0.032 µg/mL for K. pneumoniae and MIC90 values below 8 µg/mL for E. cloacae and S. marcescens.
- The activity of ceftizoxime against Gram-negative bacilli was comparable to that of cefotaxime and ceftriaxone.
- Ceftizoxime showed activity against Staphylococcus strains, but cefalotin was more potent against these species.
Conclusions:
- Ceftizoxime is a promising new cephalosporin with significant in vitro activity against Gram-negative bacilli.
- Ceftizoxime offers a comparable alternative to cefotaxime and ceftriaxone for treating infections caused by these pathogens.
- Further clinical evaluation is warranted to establish the therapeutic role of ceftizoxime.